{"id":5928,"date":"2020-04-21T11:57:22","date_gmt":"2020-04-21T11:57:22","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=5928"},"modified":"2024-06-11T15:35:57","modified_gmt":"2024-06-11T15:35:57","slug":"antiviral-compounds-potential-small-molecule-therapeutics-against-covid-19","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/antiviral-compounds-potential-small-molecule-therapeutics-against-covid-19\/","title":{"rendered":"Antiviral Compounds – Potential Small Molecule Therapeutics Against COVID-19"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, that have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trials in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and\/or viral life cycle.<\/p>\n\n\n\n

LITERATURE REFERENCES:<\/strong><\/p>\n\n\n\n

    \n
  1. Recent discovery and development of inhibitors targeting coronaviruses: T. Pillaiyar, et al.; Drug Discov. Today (Epub ahead of print)<\/strong> (2020)<\/li>\n\n\n\n
  2. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds: A.T. Ton, et al.; Mol. Inform. (Epub ahead of print)<\/strong> (2020)<\/li>\n\n\n\n
  3. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines: X. Liu & X.J. Wang; J. Genet. Genomics 47,<\/strong> 119 (2020)<\/li>\n\n\n\n
  4. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning: P. Wang, et al.; ChemRxiv (Preprint)<\/strong> (2020)<\/li>\n\n\n\n
  5. Structure of Mpro from COVID-19 virus and discovery of its inhibitors: Z. Jin, et al.; Nature (Epub ahead of print)<\/strong> (2020)<\/li>\n<\/ol>\n\n\n\n

    AdipoGen Life Sciences\u00a0offers a Selection of Antiviral Small Molecules as Potential Tools for\u00a0in vitro<\/em>\u00a0Studies of COVID-19 (not for human use).<\/strong><\/p>\n\n\n\n

    Product Name<\/strong><\/td>PID<\/strong><\/td>CAS Number<\/strong><\/td>Target<\/strong><\/td>Antiviral Activity<\/strong><\/td><\/tr>
    Aloxistatin [E-64d]<\/strong><\/td>AG-CR1-3737<\/a><\/td>88321-09-9<\/td>Viral entry
    Cathepsin L<\/td>    		Viral Replication<\/td><\/tr>
    Amastatin . hydrochloride<\/strong><\/td>AG-CP3-7003<\/a><\/td>100938-10-1<\/td>Viral entry
    ANPEP (Aminopeptidase N)<\/td>    		Viral Replication<\/td><\/tr>
    Artesunate<\/strong><\/td>AG-CN2-0469<\/a><\/td>88495-63-0<\/td>NF-\u03baB suppression<\/td>Viral Replication
    Cytokine Storm<\/td><\/tr>
    Baricitinib<\/strong><\/td>AG-CR1-3734<\/a><\/td>1187594-09-7<\/td>JAK1\/JAK2 \/ Immunomodulation
    AP-2 associated protein kinase 1 \/ Endocytosis<\/td>    		Viral Replication<\/td><\/tr>
    Boceprevir<\/strong><\/td>AG-CR1-3735<\/a><\/td>394730-60-0<\/td>Main Protease (Mpro<\/sup>)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Budesonide<\/strong><\/td>AG-CR1-3753<\/a><\/td>51333-22-3<\/td>Glucocorticod Receptors
    Inflammatory Factors<\/td>    		Viral Replication
    Cytokine Storm<\/td><\/tr>
    Camostat mesylate<\/strong><\/td>AG-CR1-3716<\/a><\/td>59721-29-8<\/td>Viral entry
    TMPRSS2<\/td>    		Viral Replication<\/td><\/tr>
    Chloroquine . diphosphate<\/strong><\/td>AG-CR1-3721<\/a><\/td>50-63-5<\/td>Lysosome function
    Zinc ionophore
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Hydroxychloroquine . sulfate<\/strong><\/td>AG-CR1-3720<\/a><\/td>747-36-4<\/td>Lysosome function
    Zinc ionophore
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Clevudine<\/strong><\/td>AG-CR1-3736<\/a><\/td>163252-36-6<\/td>RNA-dependent RNA polymerases (RdRps)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Darunavir<\/strong><\/td>AG-CR1-3712<\/a><\/td>206361-99-1<\/td>Papain-like viral protease (PLVP)<\/td>Viral Maturation\/Replication<\/td><\/tr>
    Darunavir . ethanolate<\/strong><\/td>AG-CR1-3724<\/a><\/td>635728-49-3<\/td>Papain-like viral protease (PLVP)<\/td>Viral Maturation\/Replication<\/td><\/tr>
    2-Deoxy-D-glucose<\/strong><\/td>AG-CR1-3681<\/a><\/td>154-17-6<\/td>Glycolysis\/Cell Metabolism<\/td>Viral Replication\/Cytokine Storm<\/td><\/tr>
    Dexamethasone<\/strong><\/td>AG-CR1-3742<\/a><\/td>50-02-2<\/td>Inflammatory Factors<\/td>Cytokine Storm<\/td><\/tr>
    Dexamethasone phosphate . 2Na<\/strong><\/td>AG-CR1-3744<\/a><\/td>2392-39-4<\/td>Inflammatory Factors<\/td>Cytokine Storm<\/td><\/tr>
    Dihydroartemisinin<\/strong><\/td>AG-CN2-0468<\/a><\/td>71939-50-9<\/td>NF-\u03baB suppression<\/td>Viral Replication
    Cytokine Storm<\/td><\/tr>
    Ebselen<\/strong><\/td>AG-CR1-0031<\/a><\/td>60940-34-3<\/td>Main Protease (Mpro<\/sup>)\/3C-like Protease<\/td>Viral Transcription\/Replication<\/td><\/tr>
    EIDD-2801 (Molnupiravir)<\/strong><\/td>AG-CR1-3733<\/a><\/td>2349386-89-4<\/td>RNA-dependent RNA polymerases (RdRps)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Elbasvir<\/strong><\/td>AG-CR1-3729<\/a><\/td>1370468-36-2<\/td>RdRP, Papain-like Proteinase and Helicase<\/td>Viral Replication<\/td><\/tr>
    Euphol<\/strong><\/td>AG-CN2-0541<\/a><\/td>514-47-6<\/td>Main Protease (Mpro<\/sup>)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Famotidine<\/strong><\/td>AG-CR1-3730<\/a><\/td>76824-35-6<\/td>SARS-CoV-2 papain-like protease (PLpro)<\/td>Viral Replication<\/td><\/tr>
    Favipiravir<\/strong><\/td>AG-CR1-3717<\/a><\/td>259793-96-9<\/td>RNA-dependent RNA polymerases (RdRps)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Ibudilast<\/strong><\/td>AG-CR1-3738<\/a><\/td>50847-11-5<\/td>Macrophage Inhibitory Factor (MIF)
    Immunomodulation<\/td>    		Viral Replication
    Cytokine Storm<\/td><\/tr>
    Imatinib mesylate<\/strong><\/td>AG-CR1-3725<\/a><\/td>220127-57-1<\/td>Virion fusion with endosomal membrane<\/td>Viral Replication<\/td><\/tr>
    Leupeptin . hemisulfate<\/strong><\/td>AG-CP3-7000<\/a><\/td>103476-89-7<\/td>Viral entry
    TMPRSS2<\/td>    		Viral Replication<\/td><\/tr>
    Lopinavir<\/strong><\/td>AG-CR1-3715<\/a><\/td>192725-17-0<\/td>Coronavirus endopeptidase C30 (CEP_C30)<\/td>Viral Maturation\/Replication<\/td><\/tr>
    Merafloxacin<\/strong><\/td>AG-CR1-3756<\/a><\/td>91188-00-0<\/td>Programmed -1 Ribosomal Frameshifting<\/td>Viral Replication<\/td><\/tr>
    Mycophenolic acid<\/strong><\/td>AG-CN2-0419<\/a><\/td>24280-93-1<\/td>SARS-CoV-2 papain-like protease (PLpro)<\/td>Viral Replication<\/td><\/tr>
    Nafamostat mesylate<\/strong><\/td>AG-CR1-3731<\/a><\/td>82956-11-4<\/td>Viral entry
    TMPRSS2<\/td>    		Viral Replication<\/td><\/tr>
    Nelfinavir . mesylate<\/strong><\/td>AG-CR1-3726<\/a><\/td>159989-65-8<\/td>Post-entry inhibitor<\/td>Viral Replication<\/td><\/tr>
    Niclosamide<\/strong><\/td>AG-CR1-3643<\/a><\/td>50-65-7<\/td>Endosome acidification<\/td>Viral Replication<\/td><\/tr>
    Niclosamide . ethanolamine<\/strong><\/td>AG-CR1-3644<\/a><\/td>1420-04-8<\/td>Endosome acidification<\/td>Viral Replication<\/td><\/tr>
    Nitazoxanide<\/strong><\/td>AG-CR1-3723<\/a><\/td>55981-09-4<\/td>Viral hemagglutinin
    Viral IE2<\/td>    		Viral Maturation\/
    Transcription\/Replication<\/td><\/tr>
    Opaganib<\/strong><\/td>AG-CR1-3749<\/a><\/td>915385-81-8<\/td>Sphingosine Kinase 2
    Inflammatory Factors<\/td>    		Cytokine Storm<\/td><\/tr>
    Oseltamivir . phosphate<\/strong><\/td>AG-CR1-3714<\/a><\/td>204255-11-8<\/td>Viral neuraminidase
    Release of viral particles<\/td>    		Viral Replication<\/td><\/tr>
    PX-12<\/strong><\/td>AG-CR1-3739<\/a><\/td>141400-58-0<\/td>Main Protease (Mpro<\/sup>)\/3C-like Protease<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Remdesivir<\/strong><\/td>AG-CR1-3713<\/a><\/td>1809249-37-3<\/td>RNA-dependent RNA polymerases (RdRps)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Remdesivir Metabolite
    GS-441524<\/strong><\/td>    		AG-CR1-3722<\/a><\/td>1191237-69-0<\/td>RNA-dependent RNA polymerases (RdRps)<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Ribavirin<\/strong><\/td>AG-CR1-3719<\/a><\/td>36791-04-5<\/td>RNA-dependent RNA polymerases (RdRps)
    RNA capping activity
    Viral mutation rates
    Immunomodulation<\/td>    		Viral Transcription\/Replication<\/td><\/tr>
    Ritonavir<\/strong><\/td>AG-CR1-3683<\/a><\/td>155213-67-5<\/td>Coronavirus endopeptidase C30 (CEP_C30)<\/td>Viral Maturation\/Replication<\/td><\/tr>
    Rosuvastatin . calcium salt<\/strong><\/td>AG-CR1-3728<\/a><\/td>147098-20-2<\/td>Main Protease Mpro<\/sup><\/td>Viral Replication<\/td><\/tr>
    Ruxolitinib . phosphate salt<\/strong><\/td>AG-CR1-3645<\/a><\/td>1092939-17-7<\/td>JAK1\/JAK2
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Ruxolitinib (free base)<\/strong><\/td>AG-CR1-3624<\/a><\/td>941678-49-5<\/td>JAK1\/JAK2
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Saquinavir . mesylate<\/strong><\/td>AG-CR1-3727<\/a><\/td>149845-06-7<\/td>Main Protease Mpro<\/sup><\/td>Viral Replication<\/td><\/tr>
    Shikonin<\/strong><\/td>AG-CN2-0487<\/a><\/td>517-89-5<\/td>Main Protease (Mpro<\/sup>)\/3C-like Protease<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Suramin . hexasodium salt<\/strong><\/td>AG-CR1-3575<\/a><\/td>129-46-4<\/td>Viral Entry\/Fusion
    RNA-dependent RNA polymerases (RdRps)<\/td>    		Viral Transcription\/Replication<\/td><\/tr>
    TDZD-8<\/strong><\/td>AG-CR1-3740<\/a><\/td>327036-89-5<\/td>Main Protease (Mpro<\/sup>)\/3C-like Protease<\/td>Viral Transcription\/Replication<\/td><\/tr>
    Telaprevir<\/strong><\/td>AG-CR1-3741<\/a><\/td>402957-28-2<\/td>3C-like Protease<\/td>Viral Replication<\/td><\/tr>
    Tofacitinib<\/strong><\/td>AG-CR1-3625<\/a><\/td>477600-75-2<\/td>JAK1\/JAK3
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Tofacitinib citrate<\/strong><\/td>AG-CR1-3732<\/a><\/td>540737-29-9<\/td>JAK1\/JAK3
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Tofacitinib citrate<\/strong><\/td>CDX-T0461<\/a><\/td>540737-29-9<\/td>JAK1\/JAK3
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr>
    Umifenovir . HCl [Arbidol]<\/strong><\/td>AG-CR1-3718<\/a><\/td>131707-23-8<\/td>Viral entry
    Fusion into host cells<\/td>    		Viral Replication<\/td><\/tr>
    VIP (human, mouse, rat) . AcOH [RLF-100]<\/strong><\/td>AG-CP3-0041<\/a><\/td>1444827-29-5<\/td>Viral Replication
    Immunomodulation<\/td>    		Viral Replication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    NOT FOR HUMAN USE<\/strong><\/p>\n\n\n\n

    Originally posted on adipogen.com\/covid-19<\/a><\/p>\n\n\n\n

    Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

    AdipoGen Life Sciences offers a Selection of Antiviral Small Molecules as Potential Tools for in vitro Studies of COVID-19 (not for human use).<\/p>\n","protected":false},"author":13,"featured_media":7845,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[517],"tags":[279,515,662],"class_list":["post-5928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","tag-adipogen","tag-covid-19","tag-small-molecules"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=5928"}],"version-history":[{"count":3,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5928\/revisions"}],"predecessor-version":[{"id":7859,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5928\/revisions\/7859"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/7845"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=5928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=5928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=5928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}